



10 MAR 20 2001 13 P3 21

Richard S. Morey, Esq.  
Kleinfeld, Kaplan and Becker  
1140 Nineteenth Street, N.W.  
Washington, D.C. 20036-6601

Dear Mr. Morey:

This is in response to your letter to the Food and Drug Administration (FDA) dated December 7, 2000 on behalf of Pharmavite Corporation. In your letter, you stated that Pharmavite Corporation disagrees with FDA's view that the claim "Helps maintain normal cholesterol levels" suggests that their product is intended to treat, prevent, cure, or mitigate disease. You stated that your label claim is equivalent to the claim "helps to maintain cholesterol levels that are already within the normal range," a claim that FDA sanctioned in the preamble language to the January 6, 2000 final rule (65 FR 1000 at 1018).

You are correct that FDA concluded that not all claims related to cholesterol are disease claims under the Federal Food, Drug, and Cosmetic Act (the Act). In the preamble to the final rule, FDA stated that claims about the maintenance of normal cholesterol levels did not necessarily constitute implied disease claims. We stated, however, that because "many people think of cholesterol solely in terms of the negative role of elevated cholesterol in heart disease," in order to avoid making a cholesterol maintenance claim into an implied claim, a cholesterol maintenance claim would have to explicitly disclaim the implied ability of the product to prevent the development of elevated cholesterol levels or to reduce an elevated cholesterol level. Therefore, an appropriate **structure/function** claim about maintaining cholesterol should explicitly state that the cholesterol levels that are the subject of the claim are "already within the normal range."

In a November 24, 2000, letter to Pharmavite Corporation, we informed the firm that we consider a claim about "helps maintain normal cholesterol levels" to be an implied claim to treat, prevent, cure, or mitigate hypercholesterolemia. Your December 7 letter does not change our view. We do not believe that the meaning of "to maintain normal" conveys the same meaning as "maintain levels that are already normal" with respect to the meaning it conveys when used in a claim about the effect of a product on blood cholesterol because the former claim does not clearly disclaim the implicit effect that the maintenance of normal levels is achieved by reducing an elevated cholesterol level. For this reason, we are not persuaded that the conclusion expressed in our November 24, 2000 letter is incorrect and we stand by our original determination that the claim proposed in your original submission is a disease claim that subjects your product to regulation under the drug provisions of the Act.


975 0163

LET 472

Page 2 - Mr. Richard S. Morley

Please contact us if we may be of further assistance.

Sincerely,

  
John B. Foret

Director

Division of Compliance and Enforcement  
Office of Nutritional Products, Labeling  
and Dietary Supplements  
Center for Food Safety  
and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, HFD-300

FDA, Office of the Associate Commissioner for Regulatory Affairs, Office of  
Enforcement, HFC-200

FDA, Los Angeles District Office, Compliance Branch, HFR-PA240

Page 3 - Mr. Richard S. Morley

cc:

HFA-224 (w/incoming)

HFA-305 (docket 973-0163)

HFS-22 (CCO)

HFS-800 (file, r/f)

HFS-8 11 (r/f, file)

HFD-40 (Behrman)

HFD-310

HFD-3 14 (Aronson)

HFS-605

HFV-228 (Benz)

GCF- 1 (Nickerson)

r/d:HFS-811 :RMoore:3/15/01

f / t : /\_ /01:docname:73945.adv:disc55

LAW OFFICES  
**KLEINFELD, KAPLAN AND BECKER**

73945

1140 NINETEENTH STREET, N.W.

WASHINGTON, D. C. 20036-6601

TELEPHONE (202) 223-5120

FACSIMILE (202) 223-5619


E-MAIL: kkb@kkblaw.com

ALAN H. KAPLAN  
THOMAS O. HENTELEFF  
RICHARD S. MOREY  
PETER O. SAFIR  
KINSEY S. REAGAN  
PETER R. MATHERS  
BONNIE A. BEAVERS  
DANIEL R. DWYER  
GLENN E. DAVIS  
PRESCOTT M. LASSMAN  
STACY L. EHRLICH  
JENNIFER A. DAVIDSON  
STACEY L. VALERIO

WEST COAST OFFICE:  
ONE MARKET STREET  
STUART TOWER, SUITE 1450  
SAN FRANCISCO, CA 94105-1313  
TELEPHONE (415) 538-0014  
FACSIMILE (415) 538-0016

VINCENT A. KLEINFELD  
1907-1993

December 7, 2000



Mr. John B. Foret, Director  
Division of Compliance and Enforcement  
Office of Nutritional Products, Labeling  
and Dietary Supplements  
Center for Food Safety and Applied Nutrition

Dear Mr. Foret:

We are writing to ask you to reconsider the enclosed letter of November 24, 2000, addressed to our client Pharmavite Corporation and concerning the claim: "Helps maintain normal cholesterol levels." The letter takes the position that this claim suggests an intention to treat, prevent, cure or mitigate hypercholesterolemia.

We submit that the above position is inconsistent with that taken by the agency in the preamble to its January 6, 2000 rule on Statements Made for Dietary Supplements Concerning the Effect of the Products on the Structure or Function of the Body. On page 1018 of that rule the agency states:

FDA does not agree that claims concerning maintenance of normal cholesterol levels necessarily constitute implied disease claims. Although an elevated cholesterol level is a sign of hypercholesterolemia and an important risk factor for heart disease, a cholesterol level within the normal range is not a sign or risk factor for disease. Moreover, maintaining cholesterol levels within the normal range is essential to the structure and function of the body for reasons other than prevention of disease.

65 Fed. Reg. 1018.

We also note that the agency explicitly approved the claim: "Helps to maintain cholesterol levels that are already within the normal range." See 65 Fed. Reg. 1019. This claim is identical in meaning to the claim objected to. Both claims are to "help

**KLEINFELD, KAPLAN AND BECKER**

Mr. John B. Foret, Director  
December 7, 2000  
Page 2

maintain . . . . cholesterol levels." The only difference in wording is in characterizing the "levels" of cholesterol. However, there is no difference in meaning or implication between maintaining "cholesterol levels already in the normal range" in the explicitly approved claim and maintaining "normal cholesterol levels" in Pharmavite's claim. Pharmavite's claim does not in any way suggest or imply use for cholesterol levels outside the normal range. It would therefore be unreasonable not to recognize that the language used by Pharmavite is synonymous with the explicitly approved claim.

We would appreciate your review of this question as soon as possible.

Yours very truly,



Richard S. Morey

Counsel for Pharmavite Corporation

Enclosure

cc: FDA, Center for Drug Evaluation and Research,  
Office of Compliance, HFD-300

FDA, Office of the Associate Commissioner for  
Regulatory Affairs, Office of Enforcement, HFC-200

FDA, Los Angeles District Office, Office of Compliance,  
HFR-PA140

Catherine Copp, Esq., Associate Chief Counsel of Food,  
Office of the General Counsel, GCF-1



## DEPARTMENT OF HEALTH &amp; HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Washington, DC 20204

NOV 24 2000

RECEIVED  
NOV 28 2000  
D. Kropp

Mr. David Kropp  
Acting Director, Regulatory and Consumer Affairs  
Pharmavite Corporation  
15451 San Fernando Mission Boulevard  
P.O. Box 9606  
Mission Hills, California 91346-9606

Dear Mr. Kropp:

This is in response to your letter of November 3, 2000 to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 343(r)(6) (section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act)). Your submission states that Pharmavite Corporation is making the following claim, among others, for the product Optimize Hi-Fiber:


“Helps maintain normal cholesterol levels.”

21 U.S.C. 343(r)(6) makes clear that a statement included in labeling under the authority of that section may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. The statement that you are making for this product suggests that it is intended to treat, prevent, cure, or mitigate disease, namely, hypercholesterolemia. This claim does not meet the requirements of 21 U.S.C. 343(r)(6). This claim suggests that this product is intended for use as a drug within the meaning of 21 U.S.C. 321(g)(1)(B), and that it is subject to regulation under the drug provisions of the Act. If you intend to make claims of this nature, you should contact FDA's Center for Drug Evaluation and Research (CDER), Office of Compliance, HFD-310, 7520 Standish Place, Rockville, Maryland 20855.

Page 2 - Mr. David **Kropp**

Please contact **us** if we may be of **further** assistance.

Sincerely,



**John B. Foret**

Director  
Division of Compliance and **Enforcement**  
**Office of Nutritional** Products, Labeling  
and Dietary **Supplements**  
Center for Food Safety  
and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, **HFD-300**  
FDA, Office of the Associate Commissioner for Regulatory **Affairs**, Office of  
**Enforcement, HFC-200**  
FDA, Los Angeles District Office, Office of Compliance, **HFR-PA140**